Misrepresentation of vital status follow-up: Challenging the integrity of the PLATO trial and the claimed mortality benefit of ticagrelor versus clopidogrel

International Journal of Cardiology

Volumn 169, Issue 2, 2013, Pages 145-146

  Dinicolantonio, James J ^a,b   Tomek, Ales ^a  

^a Independent Researcher/Consultant   (United States)

^b UNIVERSITY HOSPITAL MOTOL   (Czech Republic)

Author keywords

Clopidogrel; Misrepresentations; Ticagrelor

Indexed keywords

ACETYLSALICYLIC ACID; CLOPIDOGREL; PURINERGIC P2Y12 RECEPTOR; TICAGRELOR;

ARTICLE; CARDIOVASCULAR MORTALITY; CAUSE OF DEATH; DRUG EFFICACY; FOOD AND DRUG ADMINISTRATION; HUMAN; LOADING DRUG DOSE; PRIORITY JOURNAL; VALIDITY;

CLOPIDOGREL; MISREPRESENTATIONS; TICAGRELOR;

ADENOSINE; ADVISORY COMMITTEES; CLINICAL TRIALS AS TOPIC; DRUG APPROVAL; FOLLOW-UP STUDIES; HUMANS; MORTALITY; PURINERGIC P2Y RECEPTOR ANTAGONISTS; RISK ASSESSMENT; TICLOPIDINE; TREATMENT OUTCOME; VITAL STATISTICS;

EID: 84887038340     PISSN: 01675273     EISSN: 18741754     Source Type: Journal    
DOI: 10.1016/j.ijcard.2013.08.085     Document Type: Article

References (3)

1. L. Wallentin, R.C. Becker, and A. Budaj Ticagrelor versus clopidogrel in patients with acute coronary syndromes N Engl J Med 361 2009 1045 1057
2. The FDA ticagrelor review of complete response Available for download at: http://www.accessdata.fda.gov/drugsatfda-docs/nda/2011/022433Orig1s000TOC.cfm [Accessed May 10, 2012]
3. J.J. DiNicolantonio, M.M. Can, and V.L. Serebruany Lost in follow-up rates in TRACER, ATLAS ACS 2, TRITON and TRA 2P trials: Challenging PLATO mortality rates Int J Cardiol 164 3 2013 255 258